

Alexandra Lansky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1438400/publications.pdf>

Version: 2024-02-01

187
papers

23,243
citations

23500

58
h-index

7718

150
g-index

189
all docs

189
docs citations

189
times ranked

13784
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential impact of abluminal <scp>grooveâ€filled biodegradableâ€polymer sirolimusâ€eluting</scp> stent versus <scp>durableâ€polymer everolimusâ€eluting</scp> stent on and off dual antiplatelet therapy. Catheterization and Cardiovascular Interventions, 2022, 99, 357-365.	0.7	1
2	Long term outcomes of ultrathin versus standard thickness <scp>secondâ€generation</scp> drug eluting stents: <scp>Metaâ€analysis</scp> of randomized trials. Catheterization and Cardiovascular Interventions, 2022, 99, 563-574.	0.7	6
3	Safety and efficacy of dedicated guidewire, microcatheter, and guide catheter extension technologies for chronic total coronary occlusion revascularization: Primary results of the Teleflex Chronic Total Occlusion Study. Catheterization and Cardiovascular Interventions, 2022, 99, 263-270.	0.7	2
4	The â€œnitinol-constrainedâ€Chocolate balloon angioplasty: clinical applications in patients with severe atherosclerotic peripheral arterial disease. , 2022, , 673-688.		0
5	Sex-Specific Outcomes After Coronary Intravascular Lithotripsy: Aâ€Patient-Level Analysis of the Disrupt CAD Studies. , 2022, 1, 100011.		3
6	SCAI Expert Consensus Statement on Sex-Specific Considerations in Myocardial Revascularization. , 2022, 1, 100016.		2
7	ST-Segment Elevation Myocardial Infarction: Sex Differences in Incidence, Etiology, Treatment, and Outcomes. Current Cardiology Reports, 2022, 24, 529-540.	1.3	2
8	Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation, 2022, 145, 1645-1654.	1.6	12
9	Health status outcomes after spontaneous coronary artery dissection and comparison with other acute myocardial infarction: The VIRGO experience. PLoS ONE, 2022, 17, e0265624.	1.1	5
10	Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus. , 2022, 1, 100033.		0
11	Inflammatory Biomarkers in Coronary Artery Ectasia: A Systematic Review and Meta-Analysis. Diagnostics, 2022, 12, 1026.	1.3	9
12	Current Landscape and Future Directions of Coronary Revascularization in Patients With Heart Failure. JAMA Cardiology, 2022, 7, 577.	3.0	6
13	Longâ€term serial functional evaluation after implantation of the Fantom sirolimusâ€eluting bioresorbable coronary scaffold. Catheterization and Cardiovascular Interventions, 2021, 97, 431-436.	0.7	6
14	Characteristics of cardiac catheterization laboratory directors at the 2017 U.S. News & World Report top 100 U.S. cardiovascular hospitals. Catheterization and Cardiovascular Interventions, 2021, 97, E624-E626.	0.7	0
15	Impact of colchicine on mortality in patients with COVID-19: A meta-analysis. Hellenic Journal of Cardiology, 2021, 62, 374-377.	0.4	28
16	Repurposing colchicineâ€™s journey in view of drug-to-drug interactions. A review. Toxicology Reports, 2021, 8, 1389-1393.	1.6	6
17	Refining drug-eluting stent technologies: from engineering to basic science. European Heart Journal, 2021, 42, 1770-1772.	1.0	2
18	Heroes, politics and media: the unshakable medical practice in the pandemic. European Heart Journal, 2021, 42, 2622-2625.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 515-527.	1.1	53
20	Wall shear stress estimated by 3D-QCA can predict cardiovascular events in lesions with borderline negative fractional flow reserve. <i>Atherosclerosis</i> , 2021, 322, 24-30.	0.4	21
21	Atrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108724.	1.1	5
22	A randomized evaluation of the TriGuard [®] HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LESions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. <i>European Heart Journal</i> , 2021, 42, 2670-2679.	1.0	39
23	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021, 42, 4638-4651.	1.0	80
24	Outcomes of bailout percutaneous ventricular assist device versus prophylactic strategy in patients undergoing nonemergent percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E501-E512.	0.7	6
25	Meta-Analysis of Gender Disparities in In-hospital Care and Outcomes in Patients with ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2021, 147, 23-32.	0.7	34
26	Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial. <i>Circulation</i> , 2021, 143, 2143-2154.	1.6	16
27	Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations. <i>Drugs</i> , 2021, 81, 1381-1395.	4.9	10
28	When a meta-analysis equals a single large-scale trial with meaningful follow-up. <i>European Heart Journal</i> , 2021, 42, 3884-3885.	1.0	3
29	Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial. <i>Contemporary Clinical Trials</i> , 2021, 110, 106547.	0.8	4
30	Computerized technologies informing cardiac catheterization and guiding coronary intervention. <i>American Heart Journal</i> , 2021, 240, 28-45.	1.2	4
31	Coronary Revascularization in Patients Undergoing Aortic Valve Replacement for Severe Aortic Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2083-2096.	1.1	15
32	Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine. <i>Journal of Clinical Medicine</i> , 2021, 10, 5128.	1.0	2
33	Optical coherence tomography enables more accurate detection of functionally significant intermediate non-left main coronary artery stenoses than intravascular ultrasound: A meta-analysis of 6919 patients and 7537 lesions. <i>International Journal of Cardiology</i> , 2020, 301, 226-234.	0.8	19
34	Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2020, 125, 251-257.	0.7	8
35	Paclitaxel-coated balloons: a safe alternative to drug-eluting stents for coronary in-stent restenosis. <i>European Heart Journal</i> , 2020, 41, 3729-3731.	1.0	11
36	Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. <i>JAMA Cardiology</i> , 2020, 5, 92.	3.0	18

#	ARTICLE	IF	CITATIONS
37	Clinical outcomes of complex lesions treated with an abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1023-1028.	0.7	3
38	Validation of the all-comers design: Results of the TARGET-AC substudy. <i>American Heart Journal</i> , 2020, 221, 148-154.	1.2	0
39	Seasonal variation in U.S. hospitalizations for chronic limb-threatening ischemia. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1473-1480.	0.7	1
40	Sex-Specific Outcomes in Cardiovascular Device Evaluations. <i>Journal of Women's Health</i> , 2020, 29, 1246-1255.	1.5	1
41	Cerebral Embolic Protection. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 869-871.	1.1	0
42	Cerebral Embolic Protection. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2156-2158.	1.1	2
43	Predictors of Underutilization of Medical Therapy in Patients Undergoing Endovascular Revascularization for Peripheral Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2911-2918.	1.1	18
44	Computerised Methodologies for Non-Invasive Angiography-Derived Fractional Flow Reserve Assessment: A Critical Review. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-10.	0.5	13
45	<p>Reduction of Cerebral Emboli: In vitro Study with a Novel Cerebral Embolic Protection Device</p>. <i>Medical Devices: Evidence and Research</i> , 2020, Volume 13, 67-73.	0.4	1
46	Intravascular Lithotripsy for Treatment of Calcified Lower Extremity Arterial Stenosis: Initial Analysis of the Disrupt PAD III Study. <i>Journal of Endovascular Therapy</i> , 2020, 27, 473-480.	0.8	67
47	Revascularization Options for Females With Multivessel Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1009-1010.	1.1	12
48	The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent. <i>Cardiology in Review</i> , 2020, 28, 208-212.	0.6	3
49	An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. <i>European Heart Journal</i> , 2020, 41, 3504-3520.	1.0	385
50	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1017-1028.	1.2	70
51	Frequency of Management of Cardiogenic Shock With Mechanical Circulatory Support Devices According to Race. <i>American Journal of Cardiology</i> , 2020, 125, 1782-1787.	0.7	8
52	Shear Stress Estimated by Quantitative Coronary Angiography Predicts Plaques Prone to Progress and Cause Events. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2206-2219.	2.3	27
53	Clinical outcome after interventions with paclitaxel-coated balloons: a PCR statement. <i>EuroIntervention</i> , 2020, 15, 1225-1227.	1.4	3
54	Immediate and long-term impact of the COVID-19 pandemic on cardiovascular clinical trials: considerations for study conduct and endpoint determination. <i>EuroIntervention</i> , 2020, 16, 787-793.	1.4	5

#	ARTICLE	IF	CITATIONS
55	Embolic protection devices for stroke prevention during cardiac interventions. , 2020, , 941-960.		0
56	Use of Impella heart pump for management of women with peripartum cardiogenic shock. Clinical Cardiology, 2019, 42, 974-981.	0.7	31
57	Feasibility of Shockwave Coronary Intravascular Lithotripsy for the Treatment of Calcified Coronary Stenoses. Circulation, 2019, 139, 834-836.	1.6	226
58	The Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry. Journal of Women's Health, 2019, 28, 728-735.	1.5	2
59	Evaluation of anticoagulant and antiplatelet therapy after ilioacaval stenting: Factors associated with stent occlusion. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2019, 7, 527-534.	0.9	22
60	2-Year Clinical Outcomes of anÂAbluminal Grooveâ€œFilled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. JACC: Cardiovascular Interventions, 2019, 12, 1679-1687.	1.1	14
61	Sex Disparities in Cardiovascular DeviceÂEvaluations. JACC: Cardiovascular Interventions, 2019, 12, 301-308.	1.1	34
62	First-in-Human Study of Paclitaxel Drug-Coated Chocolate Coronary Percutaneous Transluminal Coronary Angioplasty Balloon Catheter in De Novo Coronary Artery Lesions. JACC: Cardiovascular Interventions, 2019, 12, 2568-2570.	1.1	0
63	Treating Post-Angioplasty Dissection in the Femoropopliteal Arteries Using the Tack Endovascular System. JACC: Cardiovascular Interventions, 2019, 12, 2375-2384.	1.1	25
64	Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: Results of Disrupt PAD II. Catheterization and Cardiovascular Interventions, 2019, 93, 335-342.	0.7	120
65	A prospective, multiâ€œcenter study of the chocolate balloon in femoropopliteal peripheral artery disease: The <sc>C</sc>hocolate <sc>BAR</sc> registry. Catheterization and Cardiovascular Interventions, 2018, 91, 1144-1148.	0.7	31
66	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation, 2018, 137, 961-972.	1.6	368
67	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Journal of the American College of Cardiology, 2018, 71, 1021-1034.	1.2	211
68	Nineâ€œmonth results of the BIOHELIXâ€œ clinical trial study: Evaluation of the PROâ€œKinetic Energy cobalt chromium bareâ€œmetal stent system. Catheterization and Cardiovascular Interventions, 2018, 92, 1030-1039.	0.7	2
69	Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial. Journal of Endovascular Therapy, 2018, 25, 68-78.	0.8	23
70	Predictors of Left Ventricular Ejection Fraction Improvement After Primary Stenting in ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents) Tj ETQq0 0 0gBT /Overlock 10 Tf		
71	Cerebral Embolic Risk During Transcatheter Mitral Valve Interventions. JACC: Cardiovascular Interventions, 2018, 11, 517-528.	1.1	13
72	Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. European Heart Journal, 2018, 39, 1687-1697.	1.0	38

#	ARTICLE	IF	CITATIONS
73	Role of Low Endothelial Shear Stress and Plaque Characteristics in the Prediction of Nonculprit Major Adverse Cardiac Events. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 462-471.	2.3	124
74	Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. <i>Lancet, The</i> , 2018, 392, 1117-1126.	6.3	46
75	Sex disparities in acute myocardial infarction care and outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E341-E347.	0.7	5
76	Carotid Disease and Stroke After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006826.	1.4	6
77	TAVI and the brain: update on definitions, evidence of neuroprotection and adjunctive pharmacotherapy. <i>EuroIntervention</i> , 2018, 14, AB53-AB63.	1.4	6
78	Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2017, 69, 679-691.	1.2	110
79	What is the best ST-segment recovery parameter to predict clinical outcome and myocardial infarct size? Amplitude, speed, and completeness of ST-segment recovery after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>Journal of Electrocardiology</i> , 2017, 50, 952-959.	0.4	6
80	Impact of Stent Size Selection on Acute and Long-Term Outcomes After Drug-Eluting Stent Implantation in De Novo Coronary Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	39
81	Safety and Performance ofÂLithoplasty for Treatment of Calcified Peripheral Artery Lesions. <i>Journal of the American College of Cardiology</i> , 2017, 70, 908-910.	1.2	96
82	Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 984-991.	0.7	18
83	Cerebral Embolic Protection: Pointâ€“Counter Point. <i>Structural Heart</i> , 2017, 1, 143-144.	0.2	0
84	Understanding neurologic complications following TAVI. <i>Interventional Cardiology Review</i> , 2017, 13, 27.	0.7	8
85	Prognostic utility of myocardial blush grade after PCI in patients with NSTEMIâ€“ACS: Analysis from the ACUITY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 215-224.	0.7	6
86	What the Clinical Event Committee Does Not See When It Comes to Stent Thrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003861.	1.4	0
87	Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. <i>American Journal of Cardiology</i> , 2016, 118, 6-16.	0.7	9
88	Diagnostic Accuracy of Fast Computational Approaches to DeriveÂFractional Flow Reserve FromÂDiagnostic Coronary Angiography. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2024-2035.	1.1	394
89	Controversies in the Treatment of Women with ST-Segment Elevation Myocardial Infarction. <i>Interventional Cardiology Clinics</i> , 2016, 5, 523-532.	0.2	3
90	Analysis of the Final DENALI Trial Data: A Prospective, Multicenter Study of the Denali Inferior Vena Cava Filter. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1531-1538.e1.	0.2	24

#	ARTICLE	IF	CITATIONS
91	Neurologic Complications of Unprotected Transcatheter Aortic Valve Implantation (from the Tj ETQq1 1 0.784314.rgBT /Overlock 10	0.7	72
92	Transcatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials). American Journal of Cardiology, 2016, 118, 396-402.	0.7	30
93	Impact of gender on infarct size, ST-segment resolution, myocardial blush and clinical outcomes after primary stenting for acute myocardial infarction: Substudy from the EMERALD trial. International Journal of Cardiology, 2016, 207, 269-276.	0.8	5
94	Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). American Journal of Cardiology, 2016, 117, 532-538.	0.7	17
95	Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). American Journal of Cardiology, 2016, 117, 186-191.	0.7	30
96	Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: Two-year results from a prospective patient-level pooled analysis of TARGET trials. Catheterization and Cardiovascular Interventions, 2015, 85, 734-743.	0.7	10
97	A prospective randomized evaluation of the TriGuard, HDH embolic DEFLECTION device during transcatheter aortic valve implantation: results from the DEFLECT III trial. European Heart Journal, 2015, 36, 2070-2078.	1.0	259
98	Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial substudy. Catheterization and Cardiovascular Interventions, 2015, 86, 1141-1150.	0.7	5
99	Local delivery of paclitaxel in the treatment of peripheral arterial disease. European Journal of Clinical Investigation, 2015, 45, 333-345.	1.7	54
100	Implications of ventricular arrhythmia bursts with normal epicardial flow, myocardial blush, and ST-segment recovery in anterior ST-elevation myocardial infarction reperfusion: A biosignature of direct myocellular injury downstream of downstream. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 51-59.	0.4	23
101	The Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients (VIRGO) Classification System. Circulation, 2015, 132, 1710-1718.	1.6	52
102	Coronary Microvascular Dysfunction. JACC: Cardiovascular Interventions, 2015, 8, 1442-1444.	1.1	5
103	Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial. EuroIntervention, 2015, 10, 1383-1390.	1.4	30
104	Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study. EuroIntervention, 2015, 11, 75-84.	1.4	58
105	Critical evaluation of stents in the peripheral arterial disease of the superficial femoral artery – focus on the paclitaxel eluting stent. Medical Devices: Evidence and Research, 2014, 7, 149.	0.4	9
106	The DENALI Trial: An Interim Analysis of a Prospective, Multicenter Study of the Denali Retrievable Inferior Vena Cava Filter. Journal of Vascular and Interventional Radiology, 2014, 25, 1497-1505.e1.	0.2	43
107	Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2014, 63, 1845-1854.	1.2	343
108	Impact of Nonculprit Vessel Myocardial Perfusion on Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2014, 7, 266-275.	1.1	2

#	ARTICLE	IF	CITATIONS
109	Impact of Cigarette Smoking on Extent of Coronary Artery Disease and Prognosis of Patients With Non- σ -ST-Segment Elevation Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2014, 7, 372-379.	1.1	45
110	Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 697	1.1	16
111	First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31-...379 patients. Open Heart, 2014, 1, e000064.	0.9	88
112	Fractional Flow Reserve From 3-Dimensional Quantitative Coronary Angiography. JACC: Cardiovascular Interventions, 2014, 7, 778-780.	1.1	8
113	Sex Differences in Long-Term Mortality After Myocardial Infarction. Circulation, 2014, 130, 757-767.	1.6	178
114	Long-Term Outcome of PCI Versus CABG in Insulin and Non- σ -Insulin-Treated Diabetic Patients. Journal of the American College of Cardiology, 2014, 64, 1189-1197.	1.2	134
115	Relation Between Coronary Calcium and Major Bleeding After Percutaneous Coronary Intervention in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 697 American Journal of Cardiology, 2014, 113, 930-935.	0.7	22
116	Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 697	1.1	16
117	Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. Atherosclerosis, 2014, 233, 224-231.	0.4	25
118	Clinical implications for diffusion-weighted MRI brain lesions associated with transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2014, 83, 502-508.	0.7	21
119	Relation of C-Reactive Protein Levels to Instability of Untreated Vulnerable Coronary Plaques (from the Acute Catheterization and Urgent Intervention Triage Strategy) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 697	0.7	23
120	Esc. Acta Cardiologica, 2014, 69, 100-108.	0.3	3
121	ESC. Acta Cardiologica, 2014, 69, 435-445.	0.3	1
122	Diagnosing and Characterizing Coronary Artery Disease in Women: Developments in Noninvasive and Invasive Imaging Techniques. Journal of Cardiovascular Translational Research, 2013, 6, 740-751.	1.1	5
123	Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 914-922.	1.1	181
124	First-in-Human Evaluation of a Bioabsorbable Polymer-Coated Sirolimus-Eluting Stent. JACC: Cardiovascular Interventions, 2013, 6, 1026-1034.	1.1	32
125	Selection and timing for invasive therapy in non-ST-segment-elevation acute coronary syndrome. Expert Review of Cardiovascular Therapy, 2013, 11, 437-445.	0.6	1
126	Challenges in cardiac device innovation: is neuroimaging an appropriate endpoint? Consensus from the 2013 Yale-UCL Cardiac Device Innovation Summit. BMC Medicine, 2013, 11, 257.	2.3	13

#	ARTICLE	IF	CITATIONS
127	A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. <i>EuroIntervention</i> , 2013, 9, 75-83.	1.4	60
128	Almanac 2013: acute coronary syndromes. <i>Turk Kardiyoloji Dernegi Arsivi</i> , 2013, 41, 755-64.	0.6	0
129	Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial. <i>Journal of Endovascular Therapy</i> , 2012, 19, 1-9.	0.8	266
130	The Generations of Drug-Eluting Stents and Outcomes in Women. <i>Interventional Cardiology Clinics</i> , 2012, 1, 183-195.	0.2	0
131	Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. <i>American Heart Journal</i> , 2012, 163, 383-391.e5.	1.2	38
132	Interventions for ST Elevation Myocardial Infarction in Women. <i>Interventional Cardiology Clinics</i> , 2012, 1, 453-465.	0.2	0
133	Strategies for Multivessel Revascularization in Patients with Diabetes. <i>New England Journal of Medicine</i> , 2012, 367, 2375-2384.	13.9	1,573
134	A gender-specific blood-based gene expression score for assessing obstructive coronary artery disease in nondiabetic patients: Results of the Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT) Trial. <i>American Heart Journal</i> , 2012, 164, 320-326.	1.2	27
135	Gender and the Extent of Coronary Atherosclerosis, Plaque Composition, and Clinical Outcomes in Acute Coronary Syndromes. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, S62-S72.	2.3	231
136	Usefulness of Noninvasive Fractional Flow Reserve Computed from Coronary Computed Tomographic Angiograms for Intermediate Stenoses Confirmed by Quantitative Coronary Angiography. <i>American Journal of Cardiology</i> , 2012, 110, 971-976.	0.7	85
137	Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years. <i>American Journal of Cardiology</i> , 2012, 110, 21-29.	0.7	20
138	Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2309-2316.	1.2	49
139	Diagnosis of Ischemia-Causing Coronary Stenoses by Noninvasive Fractional Flow Reserve Computed From Coronary Computed Tomographic Angiograms. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1989-1997.	1.2	1,058
140	Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1209-1215.	1.1	115
141	Low Stent Thrombosis Risk with the XIENCE VÂ® Everolimus-Eluting Coronary Stent: Evidence from Randomized and Single-Arm Clinical Trials. <i>Journal of Interventional Cardiology</i> , 2011, 24, 326-341.	0.5	10
142	Novel QCA methodologies and angiographic scores. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 157-165.	0.7	28
143	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 654-664.	1.1	329
144	Impact of Leukocyte Count on Mortality and Bleeding in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventions. <i>Circulation</i> , 2011, 123, 2829-2837.	1.6	62

#	ARTICLE	IF	CITATIONS
145	Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. <i>EuroIntervention</i> , 2011, 7, 307-313.	1.4	13
146	Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 644-651.	0.7	20
147	Periprocedural Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 602-610.	1.4	139
148	Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2010, 362, 1663-1674.	13.9	812
149	Nitinol Stent Implantation Versus Balloon Angioplasty for Lesions in the Superficial Femoral Artery and Proximal Popliteal Artery. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 267-276.	1.4	586
150	Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. <i>EuroIntervention</i> , 2010, 6, 437-446.	1.4	6
151	A pooled gender based analysis comparing the XIENCE V [®] everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. <i>EuroIntervention</i> , 2010, 5, 788-794.	1.4	28
152	Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. <i>EuroIntervention</i> , 2010, 6, J44-J52.	1.4	22
153	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. <i>European Heart Journal</i> , 2009, 30, 1457-1466.	1.0	315
154	Impact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 748-757.	1.1	66
155	Angiographic Surrogate End Points in Drug-Eluting Stent Trials. <i>Journal of the American College of Cardiology</i> , 2008, 51, 23-32.	1.2	153
156	Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2008, 52, 807-814.	1.2	72
157	The Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. <i>American Heart Journal</i> , 2008, 156, 44-56.	1.2	152
158	Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. <i>European Heart Journal</i> , 2007, 28, 1709-1716.	1.0	411
159	Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. <i>Lancet, The</i> , 2007, 369, 907-919.	6.3	367
160	Clinical End Points in Coronary Stent Trials. <i>Circulation</i> , 2007, 115, 2344-2351.	1.6	4,993
161	Drug-Eluting and Bare Nitinol Stents for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery: Long-term Results From the SIROCCO Trial. <i>Journal of Endovascular Therapy</i> , 2006, 13, 701-710.	0.8	468
162	Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: A subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE) ² trial. <i>American Heart Journal</i> , 2006, 151, 1032.e1-1032.e7.	1.2	37

#	ARTICLE	IF	CITATIONS
163	Distal Microcirculatory Protection During Percutaneous Coronary Intervention in Acute ST-Segment Elevation Myocardial Infarction<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2005, 293, 1063.	3.8	508
164	Sirolimus-Eluting versus Bare Nitinol Stent for Obstructive Superficial Femoral Artery Disease: The SIROCCO II Trial. Journal of Vascular and Interventional Radiology, 2005, 16, 331-338.	0.2	386
165	Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. Circulation, 2005, 111, 1611-1618.	1.6	173
166	Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. Journal of the American College of Cardiology, 2004, 44, 305-312.	1.2	171
167	Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. American Heart Journal, 2004, 148, 764-775.	1.2	231
168	Usefulness of a cobalt chromium coronary stent alloy. American Journal of Cardiology, 2003, 92, 463-466.	0.7	190
169	Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction. Circulation, 2003, 108, 2769-2775.	1.6	361
170	Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease. Circulation, 2002, 106, 1505-1509.	1.6	445
171	Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. Journal of the American College of Cardiology, 2002, 39, 591-597.	1.2	370
172	Clinical outcomes of compromised side branch (stent jail) after coronary stenting with the NIR stent. Catheterization and Cardiovascular Interventions, 2001, 54, 295-300.	0.7	25
173	Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. American Journal of Cardiology, 2001, 87, 152-156.	0.7	72
174	Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries. American Journal of Cardiology, 2001, 87, 157-162.	0.7	82
175	Effect of gender on the outcomes of contemporary percutaneous coronary intervention. American Journal of Cardiology, 2001, 88, 359-364.	0.7	157
176	Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention. Circulation, 2001, 104, 642-647.	1.6	207
177	Importance of lesion length on new device angioplasty of native coronary arteries. Catheterization and Cardiovascular Interventions, 2000, 50, 19-25.	0.7	8
178	Current perspectives on interventional treatment strategies in diabetic patients with coronary artery disease. Catheterization and Cardiovascular Interventions, 2000, 50, 245-254.	0.7	18
179	Intracoronary brachytherapy not associated with changes in major side branches. Catheterization and Cardiovascular Interventions, 2000, 51, 154-158.	0.7	4
180	Intracoronary \hat{I}^2 -Radiation Therapy Inhibits Recurrence of In-Stent Restenosis. Circulation, 2000, 101, 1895-1898.	1.6	304

#	ARTICLE	IF	CITATIONS
181	Mechanism of Lumen Enlargement During Intracoronary Stent Implantation. <i>Circulation</i> , 2000, 102, 7-10.	1.6	94
182	Atherosclerotic Plaque Burden and CK-MB Enzyme Elevation After Coronary Interventions. <i>Circulation</i> , 2000, 101, 604-610.	1.6	256
183	Procedural results and late clinical outcomes after percutaneous interventions using long (≥ 25 mm) versus short (<20 mm) stents. <i>Journal of the American College of Cardiology</i> , 2000, 35, 612-618.	1.2	45
184	Angiographic Patterns of In-Stent Restenosis. <i>Circulation</i> , 1999, 100, 1872-1878.	1.6	1,151
185	Creatine Kinase-MB Enzyme Elevation Following Successful Saphenous Vein Graft Intervention Is Associated With Late Mortality. <i>Circulation</i> , 1999, 100, 2400-2405.	1.6	217
186	Rheolytic thrombectomy in the treatment of acute limb-threatening ischemia: Immediate results and six-month follow-up of the multicenter AngioJet [®] registry. , 1998, 45, 386-393.		93
187	Procedural Results and Late Clinical Outcomes After Placement of Three or More Stents in Single Coronary Lesions. <i>Circulation</i> , 1998, 97, 1355-1361.	1.6	61